Tag: Spiromax®
-
Teva’s DuoResp Spiromax For Asthma, COPD Wins Medical Design Award – Lung Disease News
Lung Disease News Teva's DuoResp Spiromax For Asthma, COPD Wins Medical Design AwardLung Disease NewsWe are incredibly proud to be leading the way in providing people with asthma and COPD with inhalers that recognize and support their needs and long term health, and are delighted with this prestigious acknowledgment for DuoResp Spiromax,” noted Rob … View…
-
Study to Evaluate Satisfaction and Usability of DuoResp® SPIROMAX® in Asthma and COPD Treatment
Condition: Patient SatisfactionIntervention: Drug: Budesonide, Formoterol Fumarate DihydrateSponsor: Teva Pharma GmbHActive, not recruiting – verified March 2015 View full post on ClinicalTrials.gov: asthma | received in the last 14 days
-
Teva’s DuoResp Spiromax gets positive CHMP opinion to treat asthma and COPD – Pharmaceutical Business Review
Teva's DuoResp Spiromax gets positive CHMP opinion to treat asthma and COPDPharmaceutical Business ReviewDuoResp Spiromax is a new multi-dose dry-powder inhaler with a combination of budesonide, an inhaled corticosteroid for the treatment of underlying inflammation in asthma and COPD, and formoterol fumarate dihydrate, a rapid-acting and long-lasting …Teva's Symbicort generic backed for EU approvalPMLiVE10 new medicines…
-
Teva Gets Positive CHMP Opinion For DuoResp Spiromax To Treat Asthma And … – RTT News
Teva Gets Positive CHMP Opinion For DuoResp Spiromax To Treat Asthma And …RTT NewsDuoResp Spiromax is a new multi-dose dry-powder inhaler with a combination of budesonide, an inhaled corticosteroid to treat the underlying inflammation in asthma and COPD, and formoterol fumarate dihydrate, a rapid-acting and long-lasting beta2 …EU Agency backs respiratory drugs for approvalReuters UKEMA Backs…
-
Teva Gets Positive CHMP Opinion For DuoResp Spiromax To Treat Asthma And … – NASDAQ
Teva Gets Positive CHMP Opinion For DuoResp Spiromax To Treat Asthma And …NASDAQDuoResp Spiromax is a new multi-dose dry-powder inhaler with a combination of budesonide, an inhaled corticosteroid to treat the underlying inflammation in asthma and COPD, and formoterol fumarate dihydrate, a rapid-acting and long-lasting beta2 …UPDATE 1-EU Agency backs respiratory drugs for approvalReutersEMA Backs Generic…
-
Study to Evaluate the Mastery of Inhaler Technique for Budesonide Formoterol (BF) SPIROMAX® as Compared to SYMBICORT® TURBOHALER® as Treatment for Adult Patients With Asthma
Condition: AsthmaInterventions: Drug: Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX; Drug: SYMBICORT TURBOHALER budesonide and formoterol fumarateSponsors: Teva Pharmaceutical Industries; Teva Branded Pharmaceutical Products, R&D Inc.Not yet recruiting – verified February 2014 View full post on ClinicalTrials.gov: asthma | received in the last 14 days
-
Efficacy and Safety Comparison of Albuterol Spiromax® and ProAir® Hydrofluoroalkane (HFA) in Pediatric Patients
Condition: AsthmaInterventions: Drug: Albuterol Spiromax; Drug: ProAir HFA; Drug: PlaceboSponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical IndustriesNot yet recruiting – verified July 2013 View full post on ClinicalTrials.gov: asthma | received in the last 14 days
-
Open-Label Assessment of the Albuterol Spiromax® Dry Powder Inhaler (DPI)
Conditions: Asthma; Chronic Obstructive Pulmonary Disease (COPD)Intervention: Drug: Albuterol Spiromax®Sponsors: Teva Pharmaceutical Industries; Teva Pharmaceutical IndustriesNot yet recruiting – verified May 2013 View full post on ClinicalTrials.gov: asthma | received in the last 14 days